[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
Submission ::
Ethics::
Registration::
Contact us::
Site Facilities::
::
Impact Factor
Impact Factor 2022: 1.9
5-Year Impact Factor: 2.2
Cite Score 2022: 3.9
SJR 2022: 0.447
SNIP 2022: 0.538

 
..
Publication Fee
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 9, Issue 4 (Int J Mol Cell Med 2020) ::
Int J Mol Cell Med 2020, 9(4): 307-311 Back to browse issues page
PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report
Alejandro García-Muñoz1 , Nayeli Goreti Nieto-Velázquez2 , Gabriela Damian-Morales2 , Carlos Liceaga-Escalera1 , Luis Alberto Montoya-Perez1 , Madeleine Cruz-Vélez1 , Pabel Antonio Gómez-Hernández3 , Cynthia Trejo-Iriarte3 , Rodolfo Pastelin-Palacios4 , Mario Moreno-Eutimio 5
1- Maxillofacial Surgery Service, Hospital Juárez de México, Mexico City, Mexico.
2- Research División, Hospital Juárez de México, Mexico City, Mexico.
3- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (FES-Iztacala UNAM), Estado de México, México.
4- Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
5- Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (FES-Iztacala UNAM), Estado de México, México. , marioadan@inmunoquimica.com
Abstract:   (3831 Views)

Central ossifying fibroma is a benign, slow-growing tumor of mesenchymal origin with a predilection for the mandibular premolar and molar areas. The immunophenotype of T cells involved in the antitumor response against this benign tumor is unknown. In this case report, we described a case of a 48-year-old woman presenting with a very large recurrent ossifying fibroma in the mandible, which was successfully treated with hemimaxillectomy. In addition, we evaluated the expression of programmed cell death 1 receptor (PD-1), lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), CD69 (activation inducer molecule) and CD25 (α chain of the high-affinity IL-2 receptor) in T cell populations from the tumor and peripheral blood of this uncommon lesion. The patient presented recurrent ossifying fibroma, and the tumor-infiltrating and peripheral blood T cells showed expression of PD-1, LAG-3, and TIM-3, suggesting an exhausted T cell response.

Keywords: Immune checkpoint proteins, ossifying fibroma, programmed cell death 1 receptor, T-lymphocytes
Full-Text [PDF 462 kb]   (1410 Downloads)    
Type of Study: Case Report | Subject: Cancer
Received: 2020/08/2 | Accepted: 2020/11/15 | Published: 2020/11/30
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

García-Muñoz A, Nieto-Velázquez N G, Damian-Morales G, Liceaga-Escalera C, Montoya-Perez L A, Cruz-Vélez M, et al . PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report. Int J Mol Cell Med 2020; 9 (4) :307-311
URL: http://ijmcmed.org/article-1-1403-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 9, Issue 4 (Int J Mol Cell Med 2020) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.07 seconds with 39 queries by YEKTAWEB 4645